Research Papers:

Sitagliptin may reduce prostate cancer risk in male patients with type 2 diabetes

Chin-Hsiao Tseng _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:19057-19064. https://doi.org/10.18632/oncotarget.12137

Metrics: PDF 1518 views  |   HTML 2169 views  |   ?  


Chin-Hsiao Tseng1,2,3

1Department of Internal Medicine, National Taiwan University College of Medicine, Taipei, Taiwan

2Division of Endocrinology and Metabolism, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

3Division of Environmental Health and Occupational Medicine of the National Health Research Institutes, Zhunan, Taiwan

Correspondence to:

Chin-Hsiao Tseng, email: [email protected]

Keywords: incretin, National Health Insurance, prostate cancer, sitagliptin, Taiwan

Received: July 07, 2016    Accepted: September 06, 2016    Published: September 20, 2016


This retrospective cohort study evaluated the risk of prostate cancer associated with sitagliptin use in Taiwanese male patients with type 2 diabetes mellitus by using the reimbursement databases of the National Health Insurance. Male patients with newly diagnosed type 2 diabetes mellitus at an age ≥25 years between 1999 and 2010 were recruited. A total of 37,924 ever users of sitagliptin and 426,276 never users were followed until December 31, 2011. The treatment effect of sitagliptin (for ever versus never users, and for tertiles of cumulative duration of therapy) was estimated by Cox regression incorporated with the inverse probability of treatment weighting using propensity score. Analyses were also conducted in a 1:1 matched pair cohort based on 8 digits of propensity score. Results showed that during follow-up, 84 ever users and 2,549 never users were diagnosed of prostate cancer, representing an incidence of 140.74 and 240.17 per 100,000 person-years, respectively. The hazard ratio (95% confidence intervals) for ever users versus never users was 0.613 (0.493-0.763). The respective hazard ratio for the first, second, and third tertile of cumulative duration of sitagliptin use <5.9, 5.9-12.7 and >12.7 months was 0.853 (0.601-1.210), 0.840 (0.598-1.179) and 0.304 (0.191-0.483), respectively; and was 0.856 (0.603-1.214), 0.695 (0.475-1.016) and 0.410 (0.277-0.608) for cumulative dose <15,000, 15,000-33,600 and >33,600 mg, respectively. Findings were supported by analyses in the matched cohort. In conclusion, sitagliptin significantly reduces the risk of prostate cancer, especially when the cumulative duration is >12.7 months or the cumulative dose >33,600 mg.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12137